-
公开(公告)号：US20210277021A1
公开(公告)日：2021-09-09
申请号：US17254273
申请日：2019-06-18
发明人： Yanghui GUO , Xiangui HUANG , Weiwei LIAO , Lichen MENG , Taishan HU , Lei CHEN , Guoping JIANG
IPC分类号： C07D498/04 , C07D413/04 , C07D401/04 , C07D417/04 , C07D413/14
摘要： Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as an angiotensin II type 2 receptor (AT2R) antagonist, wherein definitions of substituent groups in the general formula (I) are the same as definitions in the description.
-
公开(公告)号：US20180346506A1
公开(公告)日：2018-12-06
申请号：US15535879
申请日：2015-11-11
发明人： Yanghui GUO , Shiguo ZHAO , Yue ZHANG , Liang ZHANG , Zhiqing YANG , Jian CHAI
摘要： The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products are not formed during the process, the problem of blocking of a discharge port is solved, and the method is suitable for mass industrial production and has high economic value.
-
3.发明申请公开(公告)号：US20220227699A1
公开(公告)日：2022-07-21
申请号：US17610162
申请日：2020-04-01
发明人： Yanghui GUO , Weiwei LIAO , Lichen MENG , Taishan HU , Lei CHEN , Guoping JIANG
IPC分类号： C07C233/55 , A61P25/02 , C07D267/14 , C07D223/16 , C07D413/04 , C07D413/14 , C07D413/10
摘要： The present invention relates to aromatic ring or heteroaromatic ring derivatives, a preparation method therefor and applications thereof in medicine. Specifically, the present invention relates to aromatic ring or heteroaromatic ring derivatives represented by general formula (I), a preparation method therefor and pharmaceutically acceptable salts thereof, as well as a use thereof as therapeutic agents, especially uses as angiotensin II type 2 receptor (AT2R) antagonists, wherein the definition of each substituent in the general formula (I) is the same as the definition thereof in the description.
-
4.发明公开公开(公告)号：US20230242522A1
公开(公告)日：2023-08-03
申请号：US18012269
申请日：2021-06-25
发明人： Yanghui GUO , Lichen MENG , Xiangui HUANG , Weiwei LIAO , Yongxiang GONG , Daiwang XU , Taishan HU , Lei CHEN
IPC分类号： C07D413/14
CPC分类号： C07D413/14
摘要： The present invention relates to a pharmaceutically acceptable salt of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxypyridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, a preparation method therefor, a pharmaceutical composition comprising the pharmaceutically acceptable salt thereof, and the use thereof as a therapeutic agent, in particular as an angiotensin II type-2 receptor antagonist.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
